---
document_datetime: 2026-01-30 14:55:16
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trisenox-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: trisenox-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8517331
conversion_datetime: 2026-02-01 20:20:19.724222
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## TRISENOX

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                         |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000281747 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, | 15/01/2026                          |                                             | SmPC and PL                      | SmPC new text: The following undesirable effects have been reported in clinical trials and/or post- marketing experience in newly diagnosed and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC to update the safety information based on the final results from PASS C18477-ONC-50025 listed as a category 3 study in the RMP; this is an observational Post - Authorisation Long - Term Retrospective Safety Cohort Study of Arsenic Trioxide in First Line Low - to - Intermediate - Risk Acute Promyelocytic Leukaemia (APL) Patients. The updated RMP version 3.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.4.   |            |     | relapsed/refractory APL patients. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000317382 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where                                                                                                                                | 12/01/2026 | N/A |                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| specified in the technical dossier) - Accepted  A. ADMINISTRATIVE CHANGES - A.4 Change  in the name and/or address of: a  manufacturer (including where relevant  quality control testing sites); or an ASMF  holder; or a supplier of the active substance,  starting material, reagent or intermediate  used in the manufacture of the active  substance (where specified in the technical  dossier) where no Ph. Eur. Certificate of  Suitability is part of the approved dossier; or  a manufacturer of a novel excipient (where  specified in the technical dossier) - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.e Other changes to a test  procedure (including replacement or  addition) for the active substance or a  starting material/intermediate - Accepted  B.I.c.2 Change in the specification parameters and/or limits of the immediate packaging of the active substance - B.I.c.2.z Other changes - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted B.I.b.2 Change in test procedure for active   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.b Deletion of a test procedure for the active substance or a starting material/reagent/ intermediate, if an alternative test procedure is already authorised. - Accepted                                                                                                                                                                                                                                                                                                                                                                                 |            |                 |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|
| Variation type IA / EMA/VR/0000314149 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted | 15/12/2025 | Annex II and PL |